What we are studying
This study is a multicenter, open label, non-comparative, 12-week trial to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ACZONE 7.5% in 9 to 11 year-old patients with mild, moderate, or severe acne vulgaris.
Patient participation is up to approximately 16 weeks. Patients will attend up to the
following 7 visits: Screening, Baseline/Day 1 (Screening and Baseline/Day 1 may be
combined if no washout is needed), and Weeks 1, 2, 4, 8, and 12/early exit. The total
treatment duration of trial participation for each patient is up to 12 weeks. Safety measures include adverse events, physical examination, and vital signs. Efficacy measures include the Investigator’s Global Assessment (IGA) and lesion counts in the face.
$30 per completed visit for a total of $210.